Fatostatin A is a highly potent, specific and cell permeable inhibitor of Sterol Regulatory Binding Proteins (SREBPs). It inhibits the ER-Golgi translocation of SREBPs via binding to their escort protein (SCAP). It blocks adipogenesis by inhibiting the activation of SREBP-1 and SREBP-2. It exhibits anti-proliferative effects on DU 145 cells independently of IGF-1 signaling (IC₅₀~0.1 μM). Fatostatin A can prevent increases in body weight, blood glucose and hepatic fat accumulation and reverses hyperglycemia in diabetic (ob/ob) mice, even under uncontrolled food intake. Fatostatin A may serve as a tool for gaining further insights into the regulation of SREBP.

How to Use:

• In vitro:  Fatostatin A was used at 10-20 µM in vitro.
• In vivo:  Fatostatin A was delivered intraperitoneally at 30 mg/kg once daily for 28 days in ob/ob mice model.

Reference: 

• 1. Choi Y, et al. Identification of bioactive molecules by adipogenesis profiling of organic compounds. (2003) J Biol Chem. 278(9):7320-4.
• 2. Kamisuki S, et al. A small molecule that blocks fat synthesis by inhibiting the activation of SREBP. (2009) Chem Biol. 16(8):882-92. 

Products are for research use only. Not for human use.